Guardant Health, Inc. (GH) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Guardant Health (GH) by buying shares or fractional shares at any major broker, through a healthcare or genomics ETF that holds it, or as one holding in a thematic basket. The thesis is that liquid biopsy (reading cancer signals from a simple blood draw) becomes standard care across therapy selection, cancer monitoring, and early screening, and that Guardant's FDA-approved Shield blood test opens a large colorectal-cancer screening market on top of its established oncology business. As of October 16, 2026 GH closed near $159.30 (market cap ~$21.4 billion), up about 57% year to date and about 136% over one year, with third-quarter results due November 5.
GH stock price
As of 2026-11-16, Guardant Health, Inc. (GH) last closed at $144.03, up 49.3% over the past year. Over the past 52 weeks it has traded between $78.60 and $187.22.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Guardant Health, Inc.'s investor relations page. Walnut is informational, not investment advice.
GH key stats
At $144.03 on November 16, 2026, Guardant Health, Inc. (GH) has a market cap of $19.5B.
- Market cap
- $19.5B
- Beta
- 1.66
Market cap, P/E and yield are measured at the $144.03 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Guardant Health, Inc. (GH)?
The last two weeks for Guardant Health, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- GH closed at $144.03 on November 16, 2026, down 9.3% over the past five trading days (from $158.79).
- On November 16, 2026, Guardant Health, Inc. filed an 8-K with the SEC reporting a material agreement, new debt or another financial obligation, an unregistered sale of shares and other events (Item 1.01, Item 2.03, Item 3.02, Item 8.01). Read the 8-K on sec.gov
- On November 5, 2026, Guardant Health, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Guardant Health, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 3, 2026, Guardant Health, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 10, 2026, Piper Sandler lowered its target to $190.00 from $193.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Guardant Health, Inc. (GH) latest quarter
Guardant Health reported revenue of $361 million for Q3 2026, up 36% from a year earlier (Guardant Health, Nov 5, 2026).
Source: Guardant Health Q3 2026 results, Nov 5, 2026. Full earnings breakdown
What does Guardant Health, Inc. (GH) do?
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).
The company was founded in 2011 by Helmy Eltoukhy and AmirAli Talasaz, who met at the Stanford Genome Technology Center, along with Michael Wiley. It raised over $500 million privately from backers including Sequoia, Khosla, Lightspeed, OrbiMed, and SoftBank, then listed on the Nasdaq under ticker GH in 2018. Eltoukhy and Talasaz served for years as co-CEOs and remain central figures in the business and on the board. Guardant is not yet profitable: it posted an adjusted EBITDA loss of ~$59 million in Q1 2026 and a net loss of about $120 million in Q2 2026, when revenue rose to ~$335 million. It held about $1.05 billion of cash against roughly $1.7 billion of debt at mid-2026. Earlier in 2026 management raised full-year revenue guidance to ~$1.30 to $1.32 billion, and analysts now expect about $1.36 billion; the company targets company-wide cash-flow breakeven by the end of 2027. In October 2026 Guardant360 CDx won European approval as a companion diagnostic for AstraZeneca's camizestrant (Etcamah) in advanced ER-positive breast cancer, and the company released modeling data comparing Shield's screening adherence with stool-based tests.
What's driving Guardant Health, Inc. (GH)?
1. Shield colorectal screening ramp
Shield is the first FDA-approved blood test for primary colorectal cancer screening, and screening revenue jumped to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier on ~44,000 tests. Inclusion in updated American Cancer Society guidelines, a $1,495 Medicare ADLT reimbursement rate, TRICARE military coverage, distribution through Quest Diagnostics, and a July 2026 UnitedHealth coverage decision all widen access. The bet is that a blood draw reaches the roughly one-third of eligible adults who skip colonoscopy and stool tests. On October 15, 2026 Guardant published data it says show higher screening adherence and more colorectal cancer deaths averted for Shield than for stool-based tests.
2. Core oncology growth and leverage
The oncology franchise (Guardant360 for therapy selection and Reveal for minimal residual disease) grew revenue 36% year over year with ~47% volume growth in Q1 2026. Management guides to oncology volume growth above 35% and revenue growth of ~28 to 29% for the full year. This established, higher-margin business is meant to fund the screening land grab and is expected to be free-cash-flow positive on its own. In October 2026 Guardant360 CDx was approved in Europe as the companion diagnostic for AstraZeneca's camizestrant in advanced ER-positive breast cancer, extending its role in therapy selection.
3. Path to cash-flow breakeven
Guardant is targeting company-wide cash-flow breakeven by the end of 2027, with the core business excluding screening expected to turn cash-positive sooner. Screening drove roughly $220 million of 2025 cash burn and a similar level is expected in 2026. Lowering the cost per Shield test toward ~$200 and scaling test volume are the levers management points to for closing the gap. Progress so far is gradual: the quarterly net loss was about $120 million in Q2 2026 versus about $112 million in Q1, while quarterly revenue rose from about $302 million to about $335 million.
4. Biopharma, data, and AI optionality
The Biopharma and Data segment (~$53 million in Q1 2026, up 17%) sells companion-diagnostic work, real-world data, and partnerships to drugmakers, adding a revenue stream tied to industry research budgets. Guardant also markets AI analytics layered on its large dataset of tested patients, which could support new products in monitoring and multi-cancer detection over time.
What are the risks to Guardant Health, Inc. (GH)?
Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings. Losses per share came in slightly worse than expected in Q2 2026 (-$0.42 vs -$0.39), and the balance sheet carried about $1.7 billion of debt against about $1.05 billion of cash at mid-2026. On October 15, 2026 the Patent Trial and Appeal Board rejected Guardant's challenge to a TwinStrand Biosciences duplex-sequencing patent, an intellectual-property dispute that remains open.
What is the Guardant Health, Inc. (GH) forecast?
25 analysts publish price targets on GH, averaging $200.88 as of November 2026, or +39.5% against the $144.03 share price on November 16, 2026. The published targets run from $105.00 to $240.00, a moderate spread, and the ratings split 25 buy, 0 hold, 1 sell. Over the last six months there have been 8 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full GH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is GH a buy or a sell?
We give no verdict on Guardant Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Shield colorectal screening ramp. Shield is the first FDA-approved blood test for primary colorectal cancer screening, and screening revenue jumped to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier on ~44,000 tests. The most optimistic published target, $240.00, assumes this works close to its best case.
The case against. Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. The most pessimistic target, $105.00, is roughly what GH is worth if this bites instead.
Read the full bull and bear case on GH, including what would have to change to break either one. Walnut is not an investment adviser.
Has Guardant Health, Inc. (GH) split its stock?
No. Guardant Health, Inc. (GH) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Guardant Health, Inc. (GH) valued?
Market cap, P/E and dividend yield at today's price are in the GH key stats above. The business figures below come from Guardant Health, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.18 billion; Q2 2026 ~$335 million, up ~44% YoY
- 2026 revenue outlook: guided ~$1.30 to $1.32 billion earlier in 2026; consensus now ~$1.36 billion
- Gross margin (TTM): ~65%; operating margin ~-38%
- Net income (TTM): ~-$453 million loss; EPS ~-$3.50
- Cash and debt: ~$1.05 billion cash vs ~$1.7 billion debt at mid-2026
As of October 2026: Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades near 18 times trailing sales, a multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The stock more than doubled over the year to October 2026 but sits about 17% below its 52-week high of about $191, and the November 5 report (consensus revenue ~$351 million) plus the pace of Shield adoption and the 2027 breakeven timeline matter more than any single quarter.
Which ETFs hold Guardant Health, Inc. (GH)?
Who competes with Guardant Health, Inc. (GH)?
Colorectal cancer screening
Exact Sciences is the main rival here with Cologuard, a stool-based DNA test that dominates non-invasive colorectal screening, and it is also developing its own blood-based test. Traditional colonoscopy and stool tests remain the incumbent standards Shield must win share from, and clinicians weigh Shield's convenience against colonoscopy's higher sensitivity.
Minimal residual disease and cancer monitoring
Natera (Signatera) is the leading competitor in detecting residual or recurring cancer after treatment, the market Guardant's Reveal test targets. Competition here has been contentious: a jury awarded Guardant ~$292 million in a false-advertising case against Natera, a sign of how closely the two contest oncologist mindshare.
Comprehensive genomic profiling
Roche's Foundation Medicine competes with Guardant360 in profiling tumors to match patients with targeted therapies, spanning both tissue and blood-based approaches. Other diagnostics and sequencing players circle the broader liquid-biopsy and precision-oncology market, which keeps pricing and clinical-evidence bars high.
What stocks are similar to Guardant Health, Inc. (GH)?
Other names that sit close to GH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Guardant Health, Inc. (GH)
There are three common ways to get GH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG, SCHM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so GH sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where GH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Guardant Health, Inc. (GH)
Guardant Health is a fast-growing precision-oncology company whose blood tests reached ~$335 million in Q2 2026 revenue (up about 44% year over year), but it is still unprofitable, with a trailing net loss of about $453 million, as it funds the launch of its Shield colorectal screening test toward a targeted 2027 cash-flow breakeven.
More on Guardant Health, Inc. (GH)
Whether GH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GH a buy or a sell?, and where the stock could go from here in the GH stock forecast.
For income investors, whether GH pays a dividend and how the payout looks is covered in does GH pay a dividend? And to weigh GH against a peer, read the full side-by-side comparisons: GH vs DNA and GH vs TXG.
Wondering how GH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Guardant Health, Inc.
Ask Walnut's AI anything about GH and see how it fits what you own.
FAQ
Is GH a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is rapid revenue growth, an FDA-approved Shield screening test entering a large market, and a targeted 2027 cash-flow breakeven. The bear case is ongoing losses and cash burn, reimbursement uncertainty, strong competition, and a high price-to-sales valuation. Weigh both against your own portfolio and overlap.
What does Guardant Health do?
+
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue. It sells oncology tests like Guardant360 (to match patients to targeted therapies) and Reveal (to detect residual cancer after treatment), provides testing and data services to drugmakers, and markets Shield, an FDA-approved blood test for colorectal cancer screening. It is built around the idea that a simple blood draw can guide cancer care.
What is the Shield test and why does it matter?
+
Shield is a blood test for colorectal cancer screening and the first to win full FDA approval as a primary screening option for average-risk adults 45 and older. It matters because it could reach the roughly one-third of eligible people who skip colonoscopy or stool tests. Screening revenue grew to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier, and it is the company's biggest growth driver and its largest source of cash burn.
Is Guardant Health profitable?
+
Not yet. Guardant reported a net loss of about $120 million in Q2 2026 and about $453 million over the trailing year, and it continues to burn cash, largely to fund the Shield screening launch. It held about $1.05 billion in cash at mid-2026 and targets company-wide cash-flow breakeven by the end of 2027, with the core business excluding screening expected to turn cash-positive sooner. Until then, results are judged on growth and the path to breakeven rather than earnings.
Does GH pay a dividend?
+
No. Guardant Health does not pay a dividend. As a growth-stage, pre-profit company, it reinvests capital into commercializing Shield, expanding its oncology tests, and research rather than returning cash to shareholders. Any return from GH would come from share-price appreciation, not income, which matters if you are building a portfolio for current yield.
Who are Guardant Health's main competitors?
+
In colorectal screening, Exact Sciences (Cologuard) is the main rival, alongside colonoscopy and stool tests as incumbent standards. In minimal residual disease and cancer monitoring, Natera (Signatera) leads. In comprehensive genomic profiling, Roche's Foundation Medicine competes with Guardant360. Guardant and Natera have also clashed in court, where a jury awarded Guardant about $292 million in a false-advertising case.
Why is GH stock so volatile?
+
Guardant is a high-growth, pre-profit company whose value hinges on future adoption of Shield and its oncology tests, so news moves the stock sharply. Reimbursement decisions are especially powerful: coverage announcements (such as a July 2026 UnitedHealth decision for Shield) and Medicare pricing can swing shares meaningfully. A high price-to-sales multiple also amplifies reactions to any change in the growth or breakeven outlook.
How did Guardant Health do in its latest quarter?
+
In the quarter ended June 30, 2026, Guardant reported revenue of about $335 million, up roughly 44% year over year and up from about $302 million in Q1. The net loss was about $120 million, and the loss per share of $0.42 was slightly wider than the $0.39 consensus. Third-quarter results are scheduled for November 5, 2026, with consensus near $351 million of revenue and a $0.32 loss per share.
How has GH stock performed in 2026?
+
As of the October 16, 2026 close near $159.30, GH was up about 57% year to date and about 136% over one year, within a 52-week range of roughly $64 to $191. It fell about 11% over the past month. The 25 analysts in Yahoo's consensus had an average target near $202. Past performance says nothing certain about future returns.
How can I get exposure to GH through an ETF?
+
GH appears in various healthcare, biotech, and genomics or precision-medicine ETFs, where it sits among the holdings rather than as a top position in broad funds. ETF exposure spreads single-stock risk across many names but dilutes how much any Guardant move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to the stock.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Guardant Health, Inc.'s investor relations page or your broker before making investment decisions.